Effect of Genetic Polymorphism of OATP-C (SLCO1B1) on Lipid-Lowering Response to HMG-CoA Reductase Inhibitors

Williams, 2002, Pharmacokinetic-pharmaco-dynamic drug interactions with HMG-CoA reductase inhibitors, Clin. Pharmacokinet., 41, 343, 10.2165/00003088-200241050-00003

Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group, N. Engl. J. Med., 333, 1301, 10.1056/NEJM199511163332001

Jukema, 1995, Circulation, 91, 2528, 10.1161/01.CIR.91.10.2528

Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators, N. Engl. J. Med., 335, 1001, 10.1056/NEJM199610033351401

The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, 1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N. Engl. J. Med., 339, 1349, 10.1056/NEJM199811053391902

The Kyushu Lipid Intervention Study Group, 2000, Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study, J. Atheroscler. Thromb., 7, 110, 10.5551/jat1994.7.110

Scandinavian Simvastatin Survival Study Group, 1994, Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383

Matsuzaki, 2002, Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia, Circ. J., 66, 1087, 10.1253/circj.66.1087

Mabuchi, 2002, Circ. J., 66, 1096, 10.1253/circj.66.1096

Matsuzawa, 2003, Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients, Circ. J., 67, 287, 10.1253/circj.67.287

Pitt, 1999, Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators, N. Engl. J. Med., 341, 70, 10.1056/NEJM199907083410202

Sever, 2001, Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators, J. Hypertens., 19, 1139, 10.1097/00004872-200106000-00020

Yamazaki, 1996, Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics, Pharm. Res., 13, 497, 10.1023/A:1016077517241

Hatanaka, 2000, Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events, Clin. Pharmacokinet., 39, 397, 10.2165/00003088-200039060-00002

Nakai, 2001, Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes, J. Pharmacol. Exp. Ther., 297, 861

Hsiang, 1999, A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters, J. Biol. Chem, 274, 37161, 10.1074/jbc.274.52.37161

Nozawa, 2004, Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity, Drug Metab. Dispos., 32, 291, 10.1124/dmd.32.3.291

Hirano, 2004, Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans

Michalski, 2002, A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter, J. Biol. Chem., 277, 43058, 10.1074/jbc.M207735200

Tirona, 2001, Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans, J. Biol. Chem., 276, 35669, 10.1074/jbc.M103792200

Nozawa, 2002, Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis, J. Pharmacol. Exp. Ther., 302, 804, 10.1124/jpet.302.2.804

Nishizato, 2003, Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics, Clin. Pharmacol. Ther., 73, 554, 10.1016/S0009-9236(03)00060-2

Mwinyi, 2004, Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics, Clin. Pharmacol. Ther., 75, 415, 10.1016/j.clpt.2003.12.016

Kittler, 2002, A whole genome amplification method to generate long fragments from low quantities of genomic DNA, Anal. Biochem., 300, 237, 10.1006/abio.2001.5460

Niemi, 2004, High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1), Pharmacogenetics, 14, 429, 10.1097/01.fpc.0000114750.08559.32

Evans, 1999, Pharmacogenomics: translating functional genomics into rational therapeutics, Science., 286, 487, 10.1126/science.286.5439.487

Schmitz, 2003, Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy, Clin. Chem. Lab. Med., 41, 581, 10.1515/CCLM.2003.088

Dornbrook-Lavender, 2003, Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy, Cardiovasc. Drugs Ther., 17, 75, 10.1023/A:1024212026578